Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States
When comparing patients with MM in the IQVIA PharMetrics Plus commercial insurance database, which reflects the payer perspective, significant cost savings were observed for patients treated with IRd vs DRd owing to lower OP and pharmacy costs. These findings may help inform real-world treatment and reimbursement decisions for patients with RRMM.
Authors
- Mu Cheng (ORCID: https://orcid.org/0000-0001-6831-0468)
- Selina Pi (ORCID: https://orcid.org/0000-0002-9940-1925)
- Jonathan Dabora
- Azeem Banatwala (ORCID: https://orcid.org/0000-0002-3464-4897)
- Sikander Ailawadhi (ORCID: https://orcid.org/0000-0002-8377-8111)
- Stephen J. Noga (ORCID: https://orcid.org/0000-0002-9728-0912)
- Maral DerSarkissian (ORCID: https://orcid.org/0000-0002-5528-6531)
- Melanie Young (ORCID: https://orcid.org/0000-0001-9532-9885)
- Mei Sheng Duh (ORCID: https://orcid.org/0000-0001-5035-6687)
- Melody Zhang (ORCID: https://orcid.org/0000-0001-6341-1024)
- Dasha Cherepanov (ORCID: https://orcid.org/0000-0003-2629-6025)
Institutions
- Jacksonville College (US)
- WinnMed (US)
- Takeda (United States) (US)
- Mayo Clinic in Florida (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2024-09-09
- DOI
- https://doi.org/10.18553/jmcp.2024.24085
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00